[AGRX] Agile Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 200.03 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 6.62 Change: 0.07 (1.07%)
Ext. hours: Change: 0 (0%)

chart AGRX

Refresh chart

Strongest Trends Summary For AGRX

AGRX is in the long-term down -71% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding28.74 M EPS-1 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.67
P/E To EPS Growth P/S P/BV4.1 Price/Cash Per Share
Price/Free Cash Flow-13.7 ROA-37.05% ROE-52.21% ROI
Current Ratio11.29 Quick Ratio Long Term Debt/Equity0.31 Debt Ratio0.1
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities19.52 M Cash From Investing Activities-190 K Cash From Operating Activities-5.65 M Gross Profit
Net Profit-8.54 M Operating Profit-8.01 M Total Assets68.7 M Total Current Assets54.36 M
Total Current Liabilities4.81 M Total Debt15.12 M Total Liabilities19.94 M Total Revenue
Technical Data
High 52 week5.37 Low 52 week2.04 Last close3.28 Last change1.86%
RSI30.73 Average true range0.43 Beta0.89 Volume99.56 K
Simple moving average 20 days-4.15% Simple moving average 50 days-22.43% Simple moving average 200 days-16.6%
Performance Data
Performance Week15.49% Performance Month-32.51% Performance Quart-38.23% Performance Half-17.59%
Performance Year28.13% Performance Year-to-date21.93% Volatility daily14.71% Volatility weekly32.9%
Volatility monthly67.42% Volatility yearly233.55% Relative Volume435.39% Average Volume499.87 K
New High New Low

News

2019-03-15 08:00:00 | Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress

2019-03-14 12:00:00 | AGRX: Numerous Catalysts in 2019…

2019-03-12 17:52:58 | Agile Therapeutics: 4Q Earnings Snapshot

2019-03-12 16:15:00 | Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-11 08:00:00 | Agile Therapeutics to Present at Upcoming Investor Conferences

2019-03-04 07:30:00 | Agile Therapeutics Announces $7.8 Million Private Placement

2019-02-12 10:30:00 | AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19

2019-02-11 07:30:00 | Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®

2019-02-07 08:00:00 | Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference

2019-01-11 10:45:00 | AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19…

2019-01-11 08:38:43 | The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

2019-01-10 16:15:00 | Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance

2018-12-27 07:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth

2018-12-18 08:00:00 | Agile Therapeutics to Present at Biotech Showcase 2019

2018-12-13 16:15:00 | Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®

2018-11-13 13:32:53 | Agile Therapeutics Inc NASDAQ:AGRX: Are Analysts Optimistic?

2018-11-05 13:30:00 | AGRX: Awaiting Details of Adhesion Study for Twirla®…

2018-11-02 05:12:31 | Agile Therapeutics: 3Q Earnings Snapshot

2018-11-01 16:15:00 | Agile Therapeutics Reports Third Quarter 2018 Financial Results

2018-10-24 08:00:00 | Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 Twirla® Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning NAFFP

2018-10-23 08:25:00 | New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-10-22 08:15:00 | Agile Therapeutics Gets a Path Forward for Twirla, Analysts Review and Target

2018-10-16 08:00:00 | Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics

2018-10-10 11:15:00 | AGRX: FDA Provides Path to NDA Resubmission for Twirla®…

2018-10-10 08:00:00 | Today's Research Reports on Trending Tickers: Agile Therapeutics and Horizon Pharma

2018-10-09 08:00:00 | Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA

2018-09-14 10:04:57 | Does Agile Therapeutics Inc NASDAQ:AGRX Fall With The Market?

2018-09-12 08:00:00 | Today’s Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX

2018-09-11 10:35:00 | New Growth Opportunities Jump for 3 Biotech Stocks in 2018

2018-08-29 08:10:00 | Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott — Fundamental Analysis, Key Performance Indications

2018-08-09 09:45:00 | AGRX: Formal Dispute Resolution Continues to Office of New Drugs…

2018-08-03 08:11:27 | Agile Therapeutics: 2Q Earnings Snapshot

2018-08-03 08:00:00 | Agile Therapeutics Reports Second Quarter 2018 Financial Results

2018-07-31 07:10:00 | Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks

2018-07-24 16:10:00 | FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request

2018-06-25 07:10:00 | Free Technical Research on Akorn and Three More Generic Drugs Equities

2018-06-08 14:10:00 | AGRX: Files Formal Dispute Resolution with the FDA

2018-06-08 09:20:23 | Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs

2018-06-07 16:10:00 | Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance

2018-05-22 09:25:00 | AGRX: Determining a Path Forward Following Receipt of Meeting Minutes

2018-05-21 08:00:00 | Today’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals

2018-05-18 10:44:49 | Agile Therapeutics sinks after FDA feedback on contraceptive

2018-05-18 08:10:00 | Consolidated Research: 2018 Summary Expectations for Verint, Mesabi Trust, Clearwater Paper, Agile Therapeutics, Community Trust, and Layne Christensen — Fundamental Analysis, Key Performance Indications

2018-05-18 07:30:00 | Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® AG200-15 for the Prevention of Pregnancy

2018-05-15 13:51:33 | Corium International CORI Q2 2018 Earnings Conference Call Transcript

2018-05-14 11:55:00 | AGRX: Waiting on Meeting Minutes from FDA; Planning for 2Q18 Twirla® NDA Resubmission

2018-05-11 18:51:24 | Have Investors Priced In Agile Therapeutics Inc’s NASDAQ:AGRX Growth?

2018-05-07 16:38:19 | Agile Therapeutics: 1Q Earnings Snapshot

2018-05-07 16:10:00 | Agile Therapeutics Reports First Quarter 2018 Financial Results

2018-05-02 20:58:20 | When Can We Expect A Profit From Agile Therapeutics Inc NASDAQ:AGRX?